Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Kathryn A. Whitehead(Massachusetts Institute of Technology), J. Robert Dorkin(Massachusetts Institute of Technology), Arturo J. Vegas(Massachusetts Institute of Technology), Philip Chang(Massachusetts Institute of Technology), Omid Veiseh(Massachusetts Institute of Technology), J. Matthews(Massachusetts Institute of Technology), Owen S. Fenton(Massachusetts Institute of Technology), Yunlong Zhang(Massachusetts Institute of Technology), Karsten Olejnik(Massachusetts Institute of Technology), Volkan Yesilyurt(Massachusetts Institute of Technology), Delai Chen(Massachusetts Institute of Technology), Scott Barros(Alnylam Pharmaceuticals (United States)), Boris Klebanov(Alnylam Pharmaceuticals (United States)), Tatiana I. Novobrantseva(Alnylam Pharmaceuticals (United States)), Róbert Langer(Massachusetts Institute of Technology), Daniel G. Anderson(Massachusetts Institute of Technology)
Nature Communications
June 27, 2014
10.1038/ncomms5277
Cited by 615Open Access
Full Text

Abstract

Related Papers

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi et al.|Nature|2010|2.5k
Quantification of mRNA using real-time RT-PCR
Tania Nolan, Rebecca Hands, Stephen A. Bustin|Nature Protocols|2006|2.3k
Delivery materials for siRNA therapeutics
Rosemary Kanasty, J. Robert Dorkin, Arturo J. Vegas et al.|Nature Materials|2013|1.8k
Therapeutic siRNA silencing in inflammatory monocytes in mice
Florian Leuschner, Partha Dutta, Rostic Gorbatov et al.|Nature Biotechnology|2011|835
Dynamic PolyConjugates for targeted <i>in vivo</i> delivery of siRNA to hepatocytes
David B. Rozema, David L. Lewis, Darren H. Wakefield et al.|Proceedings of the National Academy of Sciences|2007|679